Chemotherapy for Multiple Myeloma

"Cisplatin is a Phase 2 medication, which suggests that while there is some evidence of safety, there is none for efficacy."

"According to the screening process for this clinical trial, the age range of patients that can be enrolled starts at 18 and ends when the patient turns 75."

"There are currently 2286 active clinical trials for Cisplatin around the world. The first trial was conducted in 1997 and involved 300 participants. 3741 trials have been completed since then."

"Unfortunately, this study has already wrapped up recruitment. The trial was initially posted on October 1st, 2008 and was last updated September 2nd, 2022. However, there are 827 other trials for patients with multiple myeloma and 2286 clinical trials involving Cisplatin that are actively recruiting participants."

"Unfortunately, this trial is no longer recruiting patients. The listing was created on October 1st, 2008 and last updated September 2nd, 2022. There are 827 other trials for multiple myeloma and 2286 Cisplatin clinical trials that are currently looking for participants."

"This clinical trial is looking for 90 participants that have a multiple myeloma diagnosis and are between 18-75 years old. To be eligible, patients must: have newly diagnosed active MM that requires treatment, cannot have had more than one cycle of systemic MM therapy (excluding bisphosphonates and localized radiation), GEP risk score must be > or = 0.66 or LDH must be > or = 360 U/L, Zubrod < or = 2, platelet count must be > or = 50,000/uL, ejection fraction by ECHO or MUGA scan > or = 45%, adequate pulmonary"

"Cisplatin is used to fight Kaposi's sarcoma, which is often related to AIDS. It can also be employed against other conditions such as leukemia, synovitis, and Merkel cell cancer."